Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.

Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G.

Bone Marrow Transplant. 2004 Apr;33(8):823-8.

PMID:
14767499
2.

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M.

Leukemia. 2000 Jul;14(7):1310-3.

PMID:
10914557
3.

Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.

Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P.

Bone Marrow Transplant. 2002 Oct;30(7):471-3.

4.

Results of autologous stem cell transplant in multiple myeloma patients with renal failure.

Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G.

Br J Haematol. 2001 Sep;114(4):822-9.

PMID:
11564069
5.

Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.

Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B.

Clin Cancer Res. 1996 Jun;2(6):947-52.

6.

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.

Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U, Moehler T, Ho AD, Zeier M, Goldschmidt H.

Haematologica. 2006 Nov;91(11):1555-8.

7.

Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.

Knudsen LM, Nielsen B, Gimsing P, Geisler C.

Eur J Haematol. 2005 Jul;75(1):27-33.

PMID:
15946307
8.

The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.

Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow Transplantation.

Br J Haematol. 2006 Aug;134(4):385-90. Epub 2006 Jul 5.

PMID:
16822294
9.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.

Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708.

10.

Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients.

Cavo M, Baccarani M, Galieni P, Gobbi M, Tura S.

Nouv Rev Fr Hematol. 1986;28(3):147-52.

PMID:
3748798
11.

Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.

Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA.

Biol Blood Marrow Transplant. 2007 Sep;13(9):1066-72. Epub 2007 Jul 16.

12.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

PMID:
18178602
13.

[Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].

Krejcí M, Doubek M, Adam Z, Hájek R, Vorlícek J, Mayer J.

Vnitr Lek. 1997 Nov;43(11):756-8. Czech.

PMID:
9650509
14.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

15.

Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature.

Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G, Worel N, Lechner K, Greinix HT.

Ann Hematol. 1999 Apr;78(4):189-91. Review.

PMID:
10348151
16.

Multiple myeloma with renal failure. A case for intensive treatment.

Harris DC, Ibels LS, Ravich RB, Isbister JP, Wells JV.

Aust N Z J Med. 1983 Apr;13(2):163-7.

PMID:
6577835
17.

Should patients with renal failure associated with myeloma be dialysed?

Coward RA, Mallick NP, Delamore IW.

Br Med J (Clin Res Ed). 1983 Nov 26;287(6405):1575-8.

18.

Hemodialysis: an appropriate therapy in myeloma-induced renal failure.

Sharland A, Snowdon L, Joshua DE, Gibson J, Tiller DJ.

Am J Kidney Dis. 1997 Dec;30(6):786-92.

PMID:
9398122
19.

Treatment of acute renal failure due to myeloma kidney.

Bear RA, Cole EH, Lang A, Johnson M.

Can Med Assoc J. 1980 Oct 18;123(8):750-3.

20.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.

Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. Epub 2007 May 29.

Supplemental Content

Support Center